RayKnowChina Research Map
Shortlist

Fuzhou

Fujian Provincial Hospital

福建省立医院

Listed for 19 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Fujian Provincial Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌6 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌8 papers led1 open trial led
  3. Hepatocellular carcinoma肝细胞癌35 papers led5 open trials led
  4. Stomach cancer胃癌19 papers led
  5. Osteosarcoma骨肉瘤2 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  7. Neuroblastoma神经母细胞瘤1 paper led
  8. Ewing sarcoma尤文肉瘤1 paper led
  9. Aplastic anaemia再生障碍性贫血2 papers led
  10. Beta thalassaemiaβ 地中海贫血0 papers led
  11. Fanconi anaemia范可尼贫血2 papers led
  12. Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
  13. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  14. Fabry disease法布雷病1 paper led
  15. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  16. Behçet disease白塞病2 papers led
  17. IgA nephropathyIgA 肾病4 papers led
  18. Gaucher disease戈谢病1 paper led
  19. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Alport syndrome, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 6 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 1120242025: 112025

5 hospitals in Fuzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    Phase
    N/A
    Started
    2023-06
    Registry
    NCT05892354

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical University; 13 listed hospitals as study sitesFuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Liuzhou, Nanchang, Nanning, Wuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapyEBV & screeningInduction / concurrent chemotherapy
Departments in papersENT / head & neck surgeryRadiology / nuclear medicineMedical oncology
Papers it led6
  1. Nasopharyngeal cancer screening and immunotherapy efficacy evaluation based on plasma separation combined with label-free SERS technology.2025Analytica chimica acta
  2. Relevance of pyroptosis-associated genes in nasopharyngeal carcinoma diagnosis and subtype classification.2024The journal of gene medicine
  3. Identification of key pathways and genes in nasopharyngeal carcinoma based on WGCNA.2023Auris, nasus, larynx
  4. High-Precision Detection of Cellular Drug Response Based on SERS Spectrum and Multivariate Statistical Analysis.2023BiosensorsFree full text
  5. Lucialdehyde B suppresses proliferation and induces mitochondria-dependent apoptosis in nasopharyngeal carcinoma CNE2 cells.2023Pharmaceutical biologyFree full text
  6. Evaluation of nitroreductase activity in nasopharyngeal carcinoma progression by an activatable two-photon fluorescent probe.2022Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
All its trials on ClinicalTrials.gov, any status4
  1. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After ChemoradiotherapyRecruitingNCT05892354Study siteN/AStart 2023-06
  2. Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPCStatus unknownNCT05350891Study sitePhase 2Start 2022-05
  3. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  4. Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal CarcinomaStatus unknownNCT05011227Study sitePhase 2Start 2021-08
More papers found outside PubMed (not counted)3
  1. An algorithm for quantifying filopodia of multiple cells with weak fluorescence signal2025Journal of Innovative Optical Health Sciencesarticle
  2. Development of the Ninth Version of the Nasopharyngeal Cancer TNM Staging System by the American Joint Committee on Cancer and Union for International Cancer Control (AJCC/UICC): Recommendations Based on a Multicenter Validation Study and C2024SSRN Electronic Journalpreprint
  3. Study on LMP1 and lipid rafts by quantitative fluorescence resonance transfer method2023Biophysical Society of Guangdong Province Academic Forum: Precise Photons and Life Health (PPLH)conference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 8 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 2220242025: 222025

5 hospitals in Fuzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Enrolling by invitation
    A Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2023-11
    Registry
    NCT06160557

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial HospitalFuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsEarly detection & endoscopy
Departments in papersPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led8
  1. Cancer-derived fucosylated exosomal miR-6842-3p as a novel marker promotes ESCC angiogenesis and metastasis via the PTEN/AKT/mTOR/IRF1/CXCL10 axis.2026OncogeneFree full text
  2. Development a glycosylated extracellular vesicle-derived miRNA Signature for early detection of esophageal squamous cell carcinoma.2025BMC medicineFree full text
  3. GPRC5A+ myCAFs promote ESCC progression via TGF-β-induced fibroblast activation and ANXA1-mediated M2 macrophage polarization.2025International immunopharmacology
  4. Artesunate-loaded solid lipid nanoparticles resist esophageal squamous cell carcinoma by inducing Ferroptosis through inhibiting the AKT/mTOR signaling.2024Cellular signalling
  5. Cysteine protease inhibitor 1 promotes metastasis by mediating an oxidative phosphorylation/MEK/ERK axis in esophageal squamous carcinoma cancer.2024Scientific reportsFree full text
  6. Aberrant NSG1 Expression Promotes Esophageal Squamous Cell Carcinoma Cell EMT by the Activation of ERK Signaling Pathway.2023Digestive diseases and sciences
  7. MiR-942-5p inhibits tumor migration and invasion through targeting CST1 in esophageal squamous cell carcinoma.2023PloS oneFree full text
  8. Development of a panel of autoantibody against NSG1 with CEA, CYFRA21-1, and SCC-Ag for the diagnosis of esophageal squamous cell carcinoma.2021Clinica chimica acta; international journal of clinical chemistry
All its trials on ClinicalTrials.gov, any status2
  1. A Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT06160557Lead (inferred)Start 2023-11
  2. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
More papers found outside PubMed (not counted)3
  1. Effect of NSG1 on the biological behavior of esophageal squamous cell carcinoma in a zebrafish transplanted tumor model2024International Journal of Clinical and Experimental Medicinearticle
  2. Abstract CT075: Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-2023Cancer Researchconference-abstract
  3. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study2021Annals of Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 35 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
35
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 6620212022: 7720222023: 8820232024: 111120242025: 222025

6 hospitals in Fuzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06561399

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial Hospital; 2 listed hospitals as study sitesFuzhou

  2. Recruiting
    Neoadjuvant Triple Therapy for Resectable HCC
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06569498

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen

  3. Recruiting
    Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06602011

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen

  4. Enrolling by invitation
    Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07290764

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial HospitalFuzhou

  5. Enrolling by invitation
    The Efficacy of Sequential RT After Triple Therapy for uHCC
    Phase
    Not given
    Started
    2020-11
    Registry
    NCT07052448

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial HospitalFuzhou

  6. Not yet recruiting
    Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-12
    Registry
    NCT07866612

    Age 18 years to 80 years (registered criteria)

    Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai

  7. Not yet recruiting
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging, AI & early detectionRecurrence & prognosisImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineMedical oncologyGastroenterology / hepatology
Papers it led35
  1. Tumor-Infiltrating Lymphocyte Aggregation Refines Prognosis in Patients With Hepatocellular Carcinoma.2026Laboratory investigation; a journal of technical methods and pathology
  2. ​Identification of a novel m6A RNA methylation regulator-based signature for prognosis and immune landscape prediction in hepatocellular carcinoma.2025Scientific reportsFree full text
  3. Long-term survival in advanced unresectable HCC treated with transcatheter arterial chemoembolization combined with lenvatinib and PD-1 inhibitors.2025The oncologistFree full text
  4. Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicente2024Annals of surgical oncology
  5. ASO Author Reflections: Impact of Salvage Surgery in Unresectable Hepatocellular Carcinoma After Conversion Therapy: Should it be Recommended?2024Annals of surgical oncology
  6. Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics.2024Bioscience trends
  7. Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study.2024Cancer research and treatmentFree full text
  8. Silencing MFN2 Drives WNT/β-catenin Nucleation to Reduce Sorafenib Sensitivity in Hepatocellular Carcinoma Cells.2024Current medical science
  9. Novel prognostic signature for hepatocellular carcinoma using a comprehensive machine learning framework to predict prognosis and guide treatment.2024Frontiers in immunologyFree full text
  10. Coupled scRNA-seq and Bulk-seq reveal the role of HMMR in hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  11. The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors.2024Hepatology international
  12. Reply to: "Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed".2024Hepatology international
  13. Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review.2024Oncology research and treatment
  14. Expression and relationship of PD-L1, CD24, and CD47 in hepatitis B virus associated hepatocellular carcinoma.2024Scientific reportsFree full text
  15. Super-selective transcatheter vesical arterial chemoembolization with drug-loaded beads for muscle-invasive bladder cancer with hematuria.2023Abdominal radiology (New York)
  16. Comprehensive analysis and validation of SNX7 as a novel biomarker for the diagnosis, prognosis, and prediction of chemotherapy and immunotherapy response in hepatocellular carcinoma.2023BMC cancerFree full text
  17. Analyzing molecular typing and clinical application of immunogenic cell death-related genes in hepatocellular carcinoma.2023BMC cancerFree full text
  18. Textbook outcomes of hepatocellular carcinoma patients with sarcopenia: A multicenter analysis.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  19. Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study.2023Frontiers in immunologyFree full text
  20. Construction and validation of a novel IGFBP3-related signature to predict prognosis and therapeutic decision making for Hepatocellular Carcinoma.2023PeerJFree full text
  21. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making.2023Scientific reportsFree full text
  22. A Rare Case of an Esophageal Mass With Varices: Esophageal Metastasis of Hepatocellular Carcinoma.2023The American journal of gastroenterology
  23. ASO Author Reflections: Impact of Bile Duct Tumor Thrombus in Hepatocellular Carcinoma-Does it Influence Staging Systems?2022Annals of surgical oncology
  24. Impact of Bile Duct Tumor Thrombus on the Long-Term Surgical Outcomes of Hepatocellular Carcinoma Patients: A Propensity Score Matching Analysis.2022Annals of surgical oncology
  25. TRIM55 suppresses malignant biological behavior of lung adenocarcinoma cells by increasing protein degradation of Snail1.2022Cancer biology & therapyFree full text
  26. Identification of exosomal hsa-miR-483-5p as a potential biomarker for hepatocellular carcinoma via microRNA expression profiling of tumor-derived exosomes.2022Experimental cell research
  27. Should associating liver partition and portal vein ligation for staged hepatectomy be applied to hepatitis B virus-related hepatocellular carcinoma patients with cirrhosis? A multi-center study.2022HPB : the official journal of the International Hepato Pancreato Biliary Association
  28. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.2022International immunopharmacology
  29. Usefulness of AFP, PIVKA-II, and Their Combination in Diagnosing Hepatocellular Carcinoma Based on Upconversion Luminescence Immunochromatography.2022Laboratory medicine
  30. Long-Term Outcomes of Anatomic Versus Nonanatomic Resection in Hepatocellular Carcinoma Patients with Bile Duct Tumor Thrombus: A Propensity Score Matching Analysis.2021Annals of surgical oncology
  31. ASO Author Reflections: Treatment for Hepatocellular Carcinoma with Bile Duct Tumor Thrombus-Anatomic Resection Should Be Recommended.2021Annals of surgical oncology
  32. A nomogram based on combining systemic and hepatic inflammation markers for predicting microscopic bile duct tumour thrombus in hepatocellular carcinoma.2021BMC cancerFree full text
  33. Integration of IgG and IgA autoantibodies for early diagnosis of hepatocellular carcinoma.2021Clinica chimica acta; international journal of clinical chemistry
  34. Doxifluridine-based pharmacosomes delivering miR-122 as tumor microenvironments-activated nanoplatforms for synergistic treatment of hepatocellular carcinoma.2021Colloids and surfaces. B, Biointerfaces
  35. Surgical resection for hepatocellular carcinoma with bile duct tumor thrombus.2021Surgery
Chinese-language papers (not in the count)1
  1. [Primary uterine hepatoid adenocarcinoma: Clinicopathological analysis of 2 cases and literature review].2024Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciencesFree full text
All its trials on ClinicalTrials.gov, any status9
  1. Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic TherapyEnrolling by invitationNCT07290764Lead sponsorStart 2025-12
  2. Neoadjuvant Triple Therapy for Resectable HCCRecruitingNCT06569498Lead sponsorStart 2024-09
  3. Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)RecruitingNCT06561399Lead sponsorStart 2024-08
  4. Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)RecruitingNCT06602011Lead sponsorStart 2024-09
  5. The Efficacy of Sequential RT After Triple Therapy for uHCCEnrolling by invitationNCT07052448Lead sponsorStart 2020-11
  6. Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular CarcinomaNot yet recruitingNCT07866612Study siteN/AStart 2026-12
  7. 29-Gene Liver Cancer Subtype and Immunotherapy EffectivenessNot yet recruitingNCT07100236Study siteStart 2025-08
  8. A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabActive, not recruitingNCT04770896Study sitePhase 3Start 2021-04
  9. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 19 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
19
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 8820232024: 6620242025: 332025

6 hospitals in Fuzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06901531

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopySurgeryChemotherapy & combined treatment
Departments in papersMedical oncologyGastroenterology / hepatologyPathology / laboratory medicineRadiology / nuclear medicine
Papers it led19
  1. CEA-induced PI3K/AKT pathway activation through the binding of CEA to KRT1 contributes to oxaliplatin resistance in gastric cancer.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  2. Dual-energy CT for evaluating the tumor regression grade of gastric cancer after neoadjuvant chemotherapy.2025European radiology
  3. Evaluating the Potential of COL8A1 as a Therapeutic Target for Chemoresistance, Disease Progression, and a Prognostic Marker in Gastric Cancer.2025Journal of cellular and molecular medicineFree full text
  4. Identification of prognostic signatures in remnant gastric cancer through an interpretable risk model based on machine learning: a multicenter cohort study.2024BMC cancerFree full text
  5. Transparent cap-assisted blunt dissection method for a small submucosal tumor in difficult-to-reach areas of the gastric fundus.2024Gastrointestinal endoscopy
  6. Development and Validation of a Prognostic Model for Postoperative Anastomotic Recurrence in Siewert II or III Adenocarcinomas Without Neoadjuvant Therapy in an East Asian Population.2024Journal of gastrointestinal cancer
  7. Gastric epithelial neoplasm of fundic-gland mucosa lineage: representative of the low atypia differentiated gastric tumor and Ki67 may help in their identification.2024Pathology oncology research : PORFree full text
  8. SPP1+ macrophages and FAP+ fibroblasts promote the progression of pMMR gastric cancer.2024Scientific reportsFree full text
  9. The correlation between the main and minor lesions of synchronous multiple gastric neoplasms assessed gastroscopically and microscopically.2024Surgical endoscopy
  10. A modified closure method during endoscopic full-thickness resection for a gastrointestinal stromal tumor: "neck" clipping and cutting.2023Endoscopy
  11. Resected specimen extraction using a medical glove in endoscopic submucosal dissection of a large gastric submucosal tumor (with video).2023Gastrointestinal endoscopy
  12. Screening and identification of CNIH4 gene associated with cell proliferation in gastric cancer based on a large-scale CRISPR-Cas9 screening database DepMap.2023Gene
  13. Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022.2023Human vaccines & immunotherapeuticsFree full text
  14. Intraoperative Diagnosis of Serosal Invasion in Gastric Cancer by Magnifying Endoscopy with Narrow-Band Imaging for Intraoperative Measurement Decision.2023Journal of laparoendoscopic & advanced surgical techniques. Part A
  15. Characteristics of multiple early gastric cancer and gastric high-grade intraepithelial neoplasia.2023MedicineFree full text
  16. New strategy in hemorrhagic gastric cancer: A case report of complete pathological remission after neoadjuvant chemotherapy.2023MedicineFree full text
  17. Efficacy and safety of totally laparoscopic gastrectomy with uncut Roux-en-Y for gastric cancer: a dual-center retrospective study.2023World journal of surgical oncologyFree full text
  18. The safety and efficacy of laparoscopic gastrectomy for patients with locally advanced gastric cancer following neoadjuvant chemotherapy.2022Scientific reportsFree full text
  19. GPR116 overexpression correlates with poor prognosis in gastric cancer.2021MedicineFree full text
Chinese-language papers (not in the count)2
  1. [Modified reverse puncture technique for esophagojejunostomy during totally laparoscopic total gastrectomy for gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Clinicopathological features of gastric adenocarcinoma with enteroblastic differentiation: a report of twelve cases].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status7
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  2. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingNCT06901531Study sitePhase 3Start 2025-05
  3. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  4. Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer TrialStatus unknownNCT04744649Study sitePhase 2Start 2021-03
  5. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric CancerStatus unknownNCT02845986Study sitePhase 2Start 2016-09
  6. Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal MetastasisStatus unknownNCT03023436Study sitePhase 3Start 2016-01
  7. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

13 hospitals in Fuzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led2
  1. A Case of Pancreatic Ewing Sarcoma.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  2. LINC00662 facilitates osteosarcoma progression via sponging miR-103a-3p and regulating SIK2 expression.2021Journal of tissue engineering and regenerative medicine
Chinese-language papers (not in the count)1
  1. [Malignant solitary fibrous tumor with osteosarcoma components: a clinocopathological analysis of two cases].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
Earlier papers (2016–2020)2
  1. DHRS12 inhibits the proliferation and metastasis of osteosarcoma via Wnt3a/β-catenin pathway.2020Future oncology (London, England)
  2. The inhibition of microRNA-326 by SP1/HDAC1 contributes to proliferation and metastasis of osteosarcoma through promoting SMO expression.2020Journal of cellular and molecular medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

6 hospitals in Fuzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

9 hospitals in Fuzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Fuzhou for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Papers it led1
  1. A Case of Pancreatic Ewing Sarcoma.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

2 hospitals in Fuzhou for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunosuppressive treatment

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Fuzhou for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Analysis of Gene Mutation Types of Thalassemia in Fuzhou Area of China].2019Zhongguo shi yan xue ye xue za zhi

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 2 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 2.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

2 hospitals in Fuzhou for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Fuzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

5 hospitals in Fuzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Fuzhou for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Fuzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Splicing mutation of a gene within the Duchenne muscular dystrophy family.2016Genetics and molecular research : GMR

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

3 hospitals in Fuzhou for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 222025

4 hospitals in Fuzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led 1 of the 30 English-language PubMed papers on Gaucher disease with an author in mainland China, 2021–2025: 3.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Fuzhou for Gaucher disease41 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Fuzhou for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led1
  1. Mutational Analysis of a Familial Adenomatous Polyposis Pedigree with Bile Duct Polyp Phenotype.2021Canadian journal of gastroenterology & hepatology

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

福建省立医院

Fujian Provincial Hospital

福州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Fujian Provincial Hospital South Branch; Fujian Provincial Hospital and Provincial Clinical College; Fujian Provincial HOSPITAL; Fujian Provincial Hospital Jinshan Branch; Fujian Provincial Hospital South Brance

Suggest a correctionDownload the data